APO RESEARCH · REPORT
Inhaled Nitric Oxide
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Product & engineering
Understand the product.
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Selected research
Market Structure
Global Inhaled Nitric Oxide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
Read the full market overview
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
This report provides an overview of the global Inhaled Nitric Oxide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Inhaled Nitric Oxide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Inhaled Nitric Oxide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inhaled Nitric Oxide market size, projected growth trends, production technologies, key applications, and end-use industries.
Inhaled Nitric Oxide Segment by Company
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
Inhaled Nitric Oxide Segment by Type
800 ppm
100 ppm
Others
Inhaled Nitric Oxide Segment by Application
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
Inhaled Nitric Oxide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhaled Nitric Oxide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhaled Nitric Oxide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhaled Nitric Oxide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Inhaled Nitric Oxide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inhaled Nitric Oxide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inhaled Nitric Oxide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Inhaled Nitric Oxide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 800 ppm
- 100 ppm
- Others
Applications
- Near-term and Pre-term Infants PPHN
- Children and Adult ARDS
- Other Diseases
Companies covered
- Mallinckrodt
- Praxair (Linde plc)
- Air Liquide
- BOC Healthcare (Linde Group)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Inhaled Nitric Oxide Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Inhaled Nitric Oxide Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Inhaled Nitric Oxide Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Inhaled Nitric Oxide Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Inhaled Nitric Oxide Market Dynamics
- 2.1 Inhaled Nitric Oxide Industry Trends
- 2.2 Inhaled Nitric Oxide Industry Drivers
- 2.3 Inhaled Nitric Oxide Industry Opportunities and Challenges
- 2.4 Inhaled Nitric Oxide Industry Restraints
3 Inhaled Nitric Oxide Market by Manufacturers
- 3.1 Global Inhaled Nitric Oxide Revenue by Manufacturers (2021-2026)
- 3.2 Global Inhaled Nitric Oxide Sales by Manufacturers (2021-2026)
- 3.3 Global Inhaled Nitric Oxide Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Inhaled Nitric Oxide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Inhaled Nitric Oxide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Inhaled Nitric Oxide Manufacturers, Product Type & Application
- 3.7 Global Inhaled Nitric Oxide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Inhaled Nitric Oxide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Inhaled Nitric Oxide Players Market Share by Revenue in 2025
- 3.8.3 2025 Inhaled Nitric Oxide Tier 1, Tier 2, and Tier 3
4 Inhaled Nitric Oxide Market by Type
- 4.1 Inhaled Nitric Oxide Type Introduction
- 4.1.1 800 ppm
- 4.1.2 100 ppm
- 4.1.3 Others
- 4.2 Global Inhaled Nitric Oxide Sales by Type
- 4.2.1 Global Inhaled Nitric Oxide Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Inhaled Nitric Oxide Sales by Type (2021-2032)
- 4.2.3 Global Inhaled Nitric Oxide Sales Market Share by Type (2021-2032)
- 4.3 Global Inhaled Nitric Oxide Revenue by Type
- 4.3.1 Global Inhaled Nitric Oxide Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Inhaled Nitric Oxide Revenue by Type (2021-2032)
- 4.3.3 Global Inhaled Nitric Oxide Revenue Market Share by Type (2021-2032)
5 Inhaled Nitric Oxide Market by Application
- 5.1 Inhaled Nitric Oxide Application Introduction
- 5.1.1 Near-term and Pre-term Infants PPHN
- 5.1.2 Children and Adult ARDS
- 5.1.3 Other Diseases
- 5.2 Global Inhaled Nitric Oxide Sales by Application
- 5.2.1 Global Inhaled Nitric Oxide Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Inhaled Nitric Oxide Sales by Application (2021-2032)
- 5.2.3 Global Inhaled Nitric Oxide Sales Market Share by Application (2021-2032)
- 5.3 Global Inhaled Nitric Oxide Revenue by Application
- 5.3.1 Global Inhaled Nitric Oxide Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Inhaled Nitric Oxide Revenue by Application (2021-2032)
- 5.3.3 Global Inhaled Nitric Oxide Revenue Market Share by Application (2021-2032)
6 Global Inhaled Nitric Oxide Sales by Region
- 6.1 Global Inhaled Nitric Oxide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Inhaled Nitric Oxide Sales by Region (2021-2032)
- 6.2.1 Global Inhaled Nitric Oxide Sales by Region (2021-2026)
- 6.2.2 Global Inhaled Nitric Oxide Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Inhaled Nitric Oxide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Inhaled Nitric Oxide Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Inhaled Nitric Oxide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Inhaled Nitric Oxide Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Inhaled Nitric Oxide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Inhaled Nitric Oxide Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Inhaled Nitric Oxide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Inhaled Nitric Oxide Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Inhaled Nitric Oxide Revenue by Region
- 7.1 Global Inhaled Nitric Oxide Revenue by Region
- 7.1.1 Global Inhaled Nitric Oxide Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Inhaled Nitric Oxide Revenue by Region (2021-2026)
- 7.1.3 Global Inhaled Nitric Oxide Revenue by Region (2027-2032)
- 7.1.4 Global Inhaled Nitric Oxide Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Inhaled Nitric Oxide Revenue (2021-2032)
- 7.2.2 North America Inhaled Nitric Oxide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Inhaled Nitric Oxide Revenue (2021-2032)
- 7.3.2 Europe Inhaled Nitric Oxide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Inhaled Nitric Oxide Revenue (2021-2032)
- 7.4.2 Asia-Pacific Inhaled Nitric Oxide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Inhaled Nitric Oxide Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Inhaled Nitric Oxide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Mallinckrodt
- 8.1.1 Mallinckrodt Company Information
- 8.1.2 Mallinckrodt Business Overview
- 8.1.3 Mallinckrodt Inhaled Nitric Oxide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Mallinckrodt Inhaled Nitric Oxide Product Portfolio
- 8.1.5 Mallinckrodt Recent Developments
- 8.2 Praxair (Linde plc)
- 8.2.1 Praxair (Linde plc) Company Information
- 8.2.2 Praxair (Linde plc) Business Overview
- 8.2.3 Praxair (Linde plc) Inhaled Nitric Oxide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Praxair (Linde plc) Inhaled Nitric Oxide Product Portfolio
- 8.2.5 Praxair (Linde plc) Recent Developments
- 8.3 Air Liquide
- 8.3.1 Air Liquide Company Information
- 8.3.2 Air Liquide Business Overview
- 8.3.3 Air Liquide Inhaled Nitric Oxide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Air Liquide Inhaled Nitric Oxide Product Portfolio
- 8.3.5 Air Liquide Recent Developments
- 8.4 BOC Healthcare (Linde Group)
- 8.4.1 BOC Healthcare (Linde Group) Company Information
- 8.4.2 BOC Healthcare (Linde Group) Business Overview
- 8.4.3 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Product Portfolio
- 8.4.5 BOC Healthcare (Linde Group) Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Inhaled Nitric Oxide Value Chain Analysis
- 9.1.1 Inhaled Nitric Oxide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Inhaled Nitric Oxide Production Mode & Process
- 9.2 Inhaled Nitric Oxide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Inhaled Nitric Oxide Distributors
- 9.2.3 Inhaled Nitric Oxide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst